Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation

Digestive Diseases and Sciences

Volumn 55, Issue 4, 2010, Pages 1098-1105

  Ajani, Jaffer A ^a   Wang, Xuemei ^a   Izzo, Julie G ^a   Crane, Christopher H ^a   Eng, Cathy ^a   Skibber, John M ^a   Das, Prajnan ^a   Rashid, Asif ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anal carcinoma; Biomarkers of prediction; Biomarkers of prognosis; Disease free interval; Individualization of therapy

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; SONIC HEDGEHOG PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR GLI1; VASCULOTROPIN; ANTINEOPLASTIC AGENT; GLI1 PROTEIN, HUMAN; SHH PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; DATA ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HYPOTHESIS; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RADIOSENSITIVITY; UNIVARIATE ANALYSIS; ANAL CANAL; ANUS TUMOR; CELL TRANSFORMATION; ENZYME IMMUNOASSAY; FOLLOW UP; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RADIATION DOSE; SQUAMOUS CELL CARCINOMA;

ANAL CANAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUOROURACIL; FOLLOW-UP STUDIES; HEDGEHOG PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; NF-KAPPA B; PROGNOSIS; RADIOTHERAPY DOSAGE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950360188     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0812-6     Document Type: Article

References (64)

1. A Jemal R Siegel E Ward J Xu T Murray, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. ND Nigro HG Seydel B Considine VK Vaitkevicius L Leichman JJ Kinzie 1983 Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal Cancer 51 10 1826 1829 10.1002/1097-0142(19830515)51:10<1826:: AID-CNCR2820511012>3.0.CO;2-L 10.1002/1097-0142(19830515)51:10<1826::AID- CNCR2820511012>3.0.CO;2-L 1:STN:280:DyaL3s7lsFSmsA%3D%3D 6831348
3. B Sischy RL Doggett JM Krall DG Taylor WT Sause JA Lipsett, et al. 1989 Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314 J Natl Cancer Inst 81 11 850 856 10.1093/jnci/81.11.850 1:STN:280:DyaL1M3lvVymug%3D%3D 2724350
4. PJ Nilsson C Svensson S Goldman O Ljungqvist B Glimelius 2005 Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols Int J Radiat Oncol Biol Phys 61 1 92 102 10.1016/j.ijrobp.2004.03.034 15629599 (Pubitemid 40039110)
5. C Svensson S Goldman B Friberg 1993 Radiation treatment of epidermoid cancer of the anus Int J Radiat Oncol Biol Phys 27 1 67 73 1:STN:280: DyaK3sznsVKmtg%3D%3D 7690019
6. JA Ajani KA Winter LL Gunderson J Pedersen AB Benson III CR Thomas Jr, et al. 2008 Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial JAMA 299 16 1914 1921 10.1001/jama.299.16.1914 10.1001/jama.299.16.1914 1:CAS:528:DC%2BD1cXltFWgsLs%3D 18430910 (Pubitemid 351574921)
7. L Chin JW Gray 2008 Translating insights from the cancer genome into clinical practice Nature 452 7187 553 563 10.1038/nature06914 10.1038/nature06914 1:CAS:528:DC%2BD1cXktFCgt7w%3D 18385729 (Pubitemid 351483369)
8. CL Sawyers 2008 The cancer biomarker problem Nature 452 7187 548 552 10.1038/nature06913 10.1038/nature06913 1:CAS:528:DC%2BD1cXktFCgtrc%3D 18385728 (Pubitemid 351483368)
9. LJ van't Veer R Bernards 2008 Enabling personalized cancer medicine through analysis of gene-expression patterns Nature 452 7187 564 570 10.1038/nature06915 10.1038/nature06915 (Pubitemid 351483370)
10. B Vogelstein 1990 Cancer. A deadly inheritance Nature 348 6303 681 682 10.1038/348681a0 10.1038/348681a0 1:STN:280:DyaK3M%2FotV2iug%3D%3D 2259380
11. WE Naugler M Karin 2008 NF-kappaB and cancer-identifying targets and mechanisms Curr Opin Genet Dev 18 1 19 26 10.1016/j.gde.2008.01.020 10.1016/j.gde.2008.01.020 1:CAS:528:DC%2BD1cXmsVartb4%3D 18440219 (Pubitemid 351694451)
12. MS Hayden S Ghosh 2004 Signaling to NF-kappaB Genes Dev 18 18 2195 2224 10.1101/gad.1228704 10.1101/gad.1228704 1:CAS:528:DC%2BD2cXnslCntbY%3D 15371334 (Pubitemid 39209568)
13. C Rosette M Karin 1995 Cytoskeletal control of gene expression: depolymerization of microtubules activates NF-kappa B J Cell Biol 128 6 1111 1119 10.1083/jcb.128.6.1111 10.1083/jcb.128.6.1111 1:CAS:528:DyaK2MXktlKls7w%3D 7896875
14. V Bourgarel-Rey S Vallee O Rimet S Champion D Braguer A Desobry, et al. 2001 Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors Mol Pharmacol 59 5 1165 1170 1:CAS:528: DC%2BD3MXjt1aqtrY%3D 11306700
15. V Bottero V Busuttil A Loubat N Magne JL Fischel G Milano, et al. 2001 Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells Cancer Res 61 21 7785 7791 1:CAS:528:DC%2BD3MXotlakuro%3D 11691793
16. V Tergaonkar V Bottero M Ikawa Q Li IM Verma 2003 IkappaB kinase-independent IkappaBalpha degradation pathway: functional NF-kappaB activity and implications for cancer therapy Mol Cell Biol 23 22 8070 8083 10.1128/MCB.23.22.8070-8083.2003 10.1128/MCB.23.22.8070-8083.2003 1:CAS:528:DC%2BD3sXovVKjsbo%3D 14585967 (Pubitemid 37377499)
17. C Nakanishi M Toi 2005 Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat Rev Cancer 5 4 297 309 10.1038/nrc1588 10.1038/nrc1588 1:CAS:528:DC%2BD2MXivVars7Y%3D 15803156 (Pubitemid 40488635)
18. JS Russell PJ Tofilon 2002 Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha) Mol Biol Cell 13 10 3431 3440 10.1091/mbc.E02-05-0252 10.1091/mbc.E02-05-0252 1:CAS:528:DC%2BD38XotFyrsrs%3D 12388747 (Pubitemid 35191365)
19. MA Brach R Hass ML Sherman H Gunji R Weichselbaum D Kufe 1991 Ionizing radiation induces expression and binding activity of the nuclear factor kappa B J Clin Invest 88 2 691 695 10.1172/JCI115354 10.1172/JCI115354 1:CAS:528:DyaK3MXltlSksbo%3D 1864978
20. P Hainaut M Hollstein 2000 p53 and human cancer: the first ten thousand mutations Adv Cancer Res 77 81 137 10.1016/S0065-230X(08)60785-X 10.1016/S0065-230X(08)60785-X 1:CAS:528:DC%2BD3cXltl2ktQ%3D%3D 10549356
21. E White 1996 Life, death, and the pursuit of apoptosis Genes Dev 10 1 1 15 10.1101/gad.10.1.1 10.1101/gad.10.1.1 1:CAS:528:DyaK28XjslyrtA%3D%3D 8557188
22. E Meulmeester AG Jochemsen 2008 p53: a guide to apoptosis Curr Cancer Drug Targets 8 2 87 97 10.2174/156800908783769337 10.2174/156800908783769337 1:CAS:528:DC%2BD1cXjslCjtb4%3D 18336191 (Pubitemid 351347244)
23. Y Tsujimoto J Cossman E Jaffe CM Croce 1985 Involvement of the bcl-2 gene in human follicular lymphoma Science 228 4706 1440 1443 10.1126/science.3874430 10.1126/science.3874430 1:CAS:528:DyaL2MXktlaqtLk%3D 3874430
24. JC Reed 2008 Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood 111 7 3322 3330 10.1182/blood-2007-09-078162 10.1182/blood-2007-09-078162 1:CAS:528:DC%2BD1cXktlWnu7k%3D 18362212
25. T Miyashita JC Reed 1993 Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 81 1 151 157 1:CAS:528: DyaK3sXhtl2gt70%3D 8417786
26. T Miyashita JC Reed 1992 bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs Cancer Res 52 19 5407 5411 1:CAS:528:DyaK38Xmt1Grurk%3D 1394146
27. L Campos JP Rouault O Sabido P Oriol N Roubi C Vasselon, et al. 1993 High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy Blood 81 11 3091 3096 1:STN:280: DyaK3s3ntFCqtQ%3D%3D 7684624
28. JC Reed 1995 Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance Curr Opin Oncol 7 6 541 546 10.1097/00001622-199511000-00012 10.1097/00001622-199511000-00012 1:CAS:528:DyaK28XisFylsrs%3D 8547403
29. E Sharpless L Chin 2003 The INK4a/ARF locus and melanoma Oncogene 22 20 3092 3098 10.1038/sj.onc.1206461 10.1038/sj.onc.1206461 1:CAS:528: DC%2BD3sXkt12qu74%3D 12789286 (Pubitemid 36713761)
30. NE Sharpless 2005 INK4a/ARF: a multifunctional tumor suppressor locus Mutat Res 576 1-2 22 38 10.1016/j.mrfmmm.2004.08.021 1:CAS:528: DC%2BD2MXmsVaitb0%3D 15878778 (Pubitemid 40982680)
31. D Banerjee E Ercikan-Abali M Waltham B Schnieders D Hochhauser WW Li, et al. 1995 Molecular mechanisms of resistance to antifolates, a review Acta Biochim Pol 42 4 457 464 1:CAS:528:DyaK28XitVymtbc%3D 8852336
32. D Hochhauser B Schnieders E Ercikan-Abali R Gorlick R Muise-Helmericks WW Li, et al. 1996 Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line J Natl Cancer Inst 88 18 1269 1275 10.1093/jnci/88.18.1269 10.1093/jnci/88.18.1269 1:CAS:528:DyaK28XmtFWhtbs%3D 8797766
33. CJ O'Neill WG McCluggage 2006 p16 expression in the female genital tract and its value in diagnosis Adv Anat Pathol 13 1 8 15 10.1097/01.pap.0000201828. 92719.f3 10.1097/01.pap.0000201828.92719.f3 16462152 (Pubitemid 44357144)
34. AN Kalof K Cooper 2006 p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia Adv Anat Pathol 13 4 190 194 10.1097/00125480-200607000-00006 10.1097/00125480-200607000-00006 1:CAS:528:DC%2BD28XovFykuro%3D 16858153 (Pubitemid 44341655)
35. L Lum PA Beachy 2004 The Hedgehog response network: sensors, switches, and routers Science 304 5678 1755 1759 10.1126/science.1098020 10.1126/science.1098020 1:CAS:528:DC%2BD2cXkvVert78%3D 15205520 (Pubitemid 38787882)
36. M Kasper G Regl AM Frischauf F Aberger 2006 GLI transcription factors: mediators of oncogenic Hedgehog signalling Eur J Cancer 42 4 437 445 10.1016/j.ejca.2005.08.039 10.1016/j.ejca.2005.08.039 1:CAS:528: DC%2BD28XhsFOjsLg%3D 16406505 (Pubitemid 43227920)
37. M Pasca di Magliano M Hebrok 2003 Hedgehog signalling in cancer formation and maintenance Nat Rev Cancer 3 12 903 911 10.1038/nrc1229 10.1038/nrc1229 14737121
38. Z Shafaee H Schmidt W Du M Posner R Weichselbaum 2006 Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells Cancer Chemother Pharmacol 58 6 765 770 10.1007/s00280-006-0227-4 10.1007/s00280-006-0227-4 1:CAS:528:DC%2BD28XptVGqsbg%3D 16552573 (Pubitemid 44351256)
39. J Sims-Mourtada JG Izzo S Apisarnthanarax TT Wu U Malhotra R Luthra, et al. 2006 Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response Clin Cancer Res 12 21 6565 6572 10.1158/1078-0432.CCR-06-0176 10.1158/1078-0432.CCR-06-0176 1:CAS:528: DC%2BD28XhtFKitbjI 17085672 (Pubitemid 44799732)
40. J Sims-Mourtada JG Izzo J Ajani KS Chao 2007 Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport Oncogene 26 5674 5679 10.1038/sj.onc.1210356 10.1038/sj.onc.1210356 1:CAS:528:DC%2BD2sXptFemtbc%3D 17353904 (Pubitemid 47267845)
41. RK Jain 2005 Antiangiogenic therapy for cancer: current and emerging concepts Oncology 19 Suppl 3(4) 7 16 15934498 Williston Park
42. M Baumann M Krause R Hill 2008 Exploring the role of cancer stem cells in radioresistance Nat Rev Cancer 8 7 545 554 10.1038/nrc2419 10.1038/nrc2419 1:CAS:528:DC%2BD1cXnsFOkt7k%3D 18511937 (Pubitemid 351881850)
43. CE Eyler JN Rich 2008 Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis J Clin Oncol 26 17 2839 2845 10.1200/JCO.2007.15.1829 10.1200/JCO.2007.15.1829 1:CAS:528:DC%2BD1cXotlCmsr4%3D 18539962
44. EH Blackburn 2001 Switching and signaling at the telomere Cell 106 6 661 673 10.1016/S0092-8674(01)00492-5 10.1016/S0092-8674(01)00492-5 1:CAS:528:DC%2BD3MXnslGkt7c%3D 11572773 (Pubitemid 32900658)
45. H Vaziri S Benchimol 1998 Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span Curr Biol 8 5 279 282 10.1016/S0960-9822(98)70109-5 10.1016/S0960-9822(98) 70109-5 1:CAS:528:DyaK1cXhvVaitbc%3D 9501072
46. MA Rubio SH Kim J Campisi 2002 Reversible manipulation of telomerase expression and telomere length. Implications for the ionizing radiation response and replicative senescence of human cells J Biol Chem 277 32 28609 28617 10.1074/jbc.M203747200 10.1074/jbc.M203747200 1:CAS:528:DC%2BD38XmsVGqt7c%3D 12034742 (Pubitemid 41079289)
47. LM Pirzio MA Freulet-Marriere Y Bai B Fouladi JP Murnane L Sabatier, et al. 2004 Human fibroblasts expressing hTERT show remarkable karyotype stability even after exposure to ionizing radiation Cytogenet Genome Res 104 1-4 87 94 10.1159/000077470 10.1159/000077470 1:STN:280:DC%2BD2c3mt1Ohtw%3D%3D 15162019 (Pubitemid 38721057)
48. A Ahmed TO Tollefsbol 2003 Telomerase, telomerase inhibition, and cancer J Anti Aging Med 6 4 315 325 10.1089/109454503323028911 10.1089/ 109454503323028911 1:CAS:528:DC%2BD2cXjsV2gu74%3D 15142433 (Pubitemid 38580425)
49. J Mendelsohn J Baselga 2000 The EGF receptor family as targets for cancer therapy Oncogene 19 56 6550 6565 10.1038/sj.onc.1204082 10.1038/sj.onc.1204082 1:CAS:528:DC%2BD3MXhsF2ku7k%3D 11426640 (Pubitemid 32197693)
50. M Scaltriti J Baselga 2006 The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res 12 18 5268 5272 10.1158/1078-0432.CCR-05-1554 10.1158/1078-0432.CCR-05-1554 1:CAS:528: DC%2BD28XpvFShs74%3D 17000658 (Pubitemid 44497237)
51. O Riesterer L Milas KK Ang 2007 Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy J Clin Oncol 25 26 4075 4083 10.1200/JCO.2007.11.8497 10.1200/JCO.2007.11.8497 1:CAS:528:DC%2BD2sXhtlKqsbrO 17827456 (Pubitemid 47495867)
52. F Spyratos M Ferrero-Pous M Trassard K Hacene E Phillips M Tubiana-Hulin, et al. 2002 Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value Cancer 94 8 2151 2159 10.1002/cncr.10458 10.1002/cncr.10458 1:CAS:528:DC%2BD38Xjs12gtL8%3D 12001111 (Pubitemid 34411971)
53. P Das S Bhatia C Eng JA Ajani JM Skibber MA Rodriguez-Bigas, et al. 2007 Predictors and patterns of recurrence after definitive chemoradiation for anal cancer Int J Radiat Oncol Biol Phys 68 3 794 800 10.1016/j.ijrobp.2006.12.052 17379452 (Pubitemid 46818735)
54. JG Izzo U Malhotra TT Wu J Ensor R Luthra JH Lee, et al. 2006 Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma J Clin Oncol 24 5 748 754 10.1200/JCO.2005.03.8810 10.1200/JCO.2005.03.8810 1:CAS:528:DC%2BD28XitVGisbw%3D 16401681 (Pubitemid 46622041)
55. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Stat Assoc 53 457 481 10.2307/2281868 10.2307/2281868
56. DR Cox 1972 Regression models and life tables (with discussion) J R Stat Soc B 34 187 220
57. Therneau TM, Grambsch PM. P. M. Modeling Survival Data, Extending the Cox Model. New York: Springer-Verlag; 2000.
58. Venables WN, Ripley BD. Modern Applied Statistics with Splus. 3rd ed. New York: Springer; 1999.
59. J Zhang CR Martins ZB Fansler KL Roemer EA Kincaid KS Gustafson, et al. 2005 DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma Clin Cancer Res 11 18 6544 6549 10.1158/1078-0432.CCR-05-0374 10.1158/1078-0432.CCR-05-0374 1:CAS:528:DC%2BD2MXhtVShsb%2FO 16166431 (Pubitemid 41338993)
60. H Patel G Polanco-Echeverry S Segditsas E Volikos A McCart C Lai, et al. 2007 Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma Int J Cancer 121 12 2668 2673 10.1002/ijc.23028 10.1002/ijc.23028 1:CAS:528:DC%2BD2sXhtl2qsL3L 17721920 (Pubitemid 350136410)
61. PJ Nilsson C Lenander C Rubio G Auer O Ljungqvist B Glimelius 2006 Prognostic significance of Cyclin A in epidermoid anal cancer Oncol Rep 16 3 443 449 1:CAS:528:DC%2BD28XptVahu78%3D 16865241
62. O Bruland O Fluge H Immervoll L Balteskard M Myklebust A Skarstein, et al. 2008 Gene expression reveals two distinct groups of anal carcinomas with clinical implications Br J Cancer 98 7 1264 1273 10.1038/sj.bjc.6604285 10.1038/sj.bjc.6604285 1:CAS:528:DC%2BD1cXktVKhsro%3D 18349847 (Pubitemid 351481671)
63. G Alvarez A Perry BR Tan HL Wang 2006 Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification Mod Pathol 19 7 942 949 10.1038/modpathol.3800608 10.1038/modpathol.3800608 1:CAS:528:DC%2BD28Xls1KitLw%3D 16648870
64. P Gervaz D Hahnloser BG Wolff SA Anderson J Cunningham RW Beart Jr, et al. 2004 Molecular biology of squamous cell carcinoma of the anus: a comparison of HIV-positive and HIV-negative patients J Gastrointest Surg 8 8 1024 1030 10.1016/j.gassur.2004.08.013 10.1016/j.gassur.2004.08.013 15585390 discussion 31 (Pubitemid 39600645)